P069 Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Is there a clinical benefit?

MLA

Gedske Daugaard, et al. “P069 Low-Dose Prednisolone in First-Line Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer. Is There a Clinical Benefit?” European Urology Supplements, vol. 13, Nov. 2014, pp. 134–35. EBSCOhost, https://doi.org/10.1016/s1569-9056(14)61292-6.

APA

Gedske Daugaard, Lisa Sengeløv, P. Kongsted, I.M. Svane, & H. Lindberg. (2014). P069 Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Is there a clinical benefit? European Urology Supplements, 13, 134–135. https://doi.org/10.1016/s1569-9056(14)61292-6

Chicago

Gedske Daugaard, Lisa Sengeløv, P. Kongsted, I.M. Svane, and H. Lindberg. 2014. “P069 Low-Dose Prednisolone in First-Line Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer. Is There a Clinical Benefit?” European Urology Supplements 13 (November): 134–35. doi:10.1016/s1569-9056(14)61292-6.